Timing correction: CVS is scheduled to report today, Wednesday, August 5, 2026, before the market opens, with its earnings call at 8:00 a.m. ET—not tomorrow. (investors.cvshealth.com)
CVS enters Q2 with substantially more credibility—and a much higher bar—than it had three months ago. The first quarter featured a large Aetna earnings recovery, a $0.30 increase to full-year adjusted EPS guidance, and better-than-expected execution across the company. CVS shares closed at $104.45 on August 4, approximately 29% above their May 5 close, so the market is no longer pricing the story as an early-stage turnaround.
The central question is therefore not whether CVS can meet the Q2 consensus. It is whether management can demonstrate that the improvement at Aetna is based on durable current-year medical-cost performance, rather than favorable reserve development and unusually favorable first-quarter seasonality.
A clean quarter probably requires three things:
| Metric | Q2 2026 expectation / benchmark |
|---|---|
| Adjusted EPS consensus | Approximately $1.83–$1.84 |
| Revenue consensus | Approximately $100.1 billion |
| Q2 2025 adjusted EPS | $1.81 |
| Q2 2025 revenue | $98.9 billion |
| Current FY2026 adjusted EPS guidance | $7.30–$7.50 |
| FY2026 revenue guidance | At least $405 billion |
| FY2026 operating cash flow guidance | At least $9.5 billion |
| FY2026 adjusted operating income | $15.53–$15.87 billion |
Current third-party estimates call for adjusted EPS around $1.84 and revenue around $100.09 billion. (benzinga.com) CVS reported $1.81 of adjusted EPS and $98.9 billion of revenue in Q2 2025. (cvshealth.com)
Management said after Q1 that roughly 60% of 2026 earnings should fall in the first half. Applied to the $7.30–$7.50 full-year range, that implies first-half EPS of approximately $4.38–$4.50. After Q1’s $2.57, the corresponding Q2 range is roughly $1.81–$1.93. That puts consensus near the lower half of the company-implied range.
At the August 4 closing price, CVS trades at roughly 14.1 times the midpoint of its 2026 adjusted EPS guidance—not demanding in absolute terms, but materially less forgiving after the stock’s rally.
This is the most important part of the report.
In Q1, Health Care Benefits delivered:
CVS raised its full-year Health Care Benefits adjusted operating income outlook to $4.0–$4.34 billion, while retaining its full-year MBR forecast of 90.5%, plus or minus 50 basis points. Management explicitly said it had not incorporated the pockets of current-year medical-cost outperformance seen in Q1 into guidance. (investors.cvshealth.com)
Current-year utilization: The market will want detail on inpatient, outpatient, physician, pharmacy and supplemental-benefit trends, particularly in Medicare Advantage.
Prior-year development: Additional favorable development would help reported earnings, but investors should avoid capitalizing reserve releases as if they were recurring operating improvement.
Medicare versus commercial performance: Commercial pricing and retention appeared strong in Q1. Medicare is the larger strategic issue because CVS is still working toward target margins by 2028.
Medicaid rates: Management previously said state rate updates were beginning to align better with member acuity. Confirmation would reduce the risk that another government business becomes a source of cost pressure.
Reserve adequacy: Days claims payable were 42.9 days at the end of Q1, up four days sequentially. Management’s explanation of reserve confidence will be important if utilization accelerated during Q2.
Recent peer results provide a constructive but not uniform backdrop. UnitedHealth raised its 2026 outlook, while Centene raised guidance after reporting better-than-expected medical-cost performance. (unitedhealthgroup.com) That increases the likelihood that investors will expect CVS to show similarly tangible progress rather than merely reiterate cautious assumptions.
The strongest outcome would be an MBR and Health Care Benefits profit result supported by current-year claims performance, accompanied by management saying that the Q1 pockets of outperformance continued through Q2.
Health Services—primarily Caremark plus health care delivery—is likely to be the most complicated segment to interpret.
In Q1:
The original 2026 outlook contemplated Health Services adjusted operating income of more than $7.2 billion, driven by modest Caremark growth and improved health care delivery performance.
A sequential decline in Health Services profit would not necessarily be a negative surprise. Investors should instead focus on:
CVS began excluding branded Stelara from its commercial template formularies on July 1 in favor of biosimilars. Because that occurred after Q2 ended, it is principally a second-half and forward-looking catalyst, not a meaningful contributor to the reported quarter.
The bearish read would be that Health Services’ weakness is no longer merely a known transition cost. Any indication that rebate guarantees, client price concessions or regulatory changes are creating incremental pressure beyond existing guidance would challenge the company’s claim that Caremark can maintain attractive long-term margins.
Pharmacy & Consumer Wellness had mixed Q1 results:
Despite the decline, CVS raised full-year segment adjusted operating income guidance to at least $6.18 billion. That implies a meaningful improvement after Q1.
CVS said in Q1 that GLP-1 market share had improved approximately 200 basis points and that CostVantage had neutralized what was previously a loss-making category. Confirmation that those economics remain stable would be encouraging.
CVS raised 2026 adjusted EPS guidance after Q1 to $7.30–$7.50, up from $7.00–$7.20, and raised revenue guidance to at least $405 billion. (investors.cvshealth.com)
Because Q1 was so strong, a simple reiteration would not automatically be bad. Management deliberately maintained conservative assumptions for current-year medical costs. However, expectations have risen alongside the stock.
The market may be particularly sensitive to guidance because peer managed-care stocks have recently demonstrated that a quarterly EPS beat is not always sufficient when the forward outlook fails to improve.
CVS generated $4.25 billion of operating cash flow in Q1 and ended the quarter with a leverage ratio of 3.84 times. Full-year operating cash flow guidance stands at at least $9.5 billion.
Management remains focused on deleveraging and has not included share repurchases in its 2026 outlook. The relevant questions are:
A buyback announcement appears unlikely to be necessary for a positive report. A clearer timeline for returning to more balanced capital deployment, however, would add support to the equity story.
CVS has said that the final 2027 rate notice was an improvement but remains insufficient to offset elevated medical-cost trends. Investors should listen for:
Management has argued that federal changes broadly validate CVS’s shift toward transparent, net-cost pricing. The more immediate concern is differing state regulation, including Tennessee legislation scheduled to become effective in 2028.
The investment issue is not simply whether CVS challenges these rules legally. It is whether management can continue promising mid-teens EPS growth through 2028 while absorbing changes to specialty-pharmacy and PBM economics.
Oak Street Health was reportedly tracking broadly to plan in Q1, but the segment remains on a multiyear path toward breakeven. Investors should look for measurable evidence on:
Health100 is expected to launch later in 2026. The current financial outlook includes its development costs but does not assume meaningful revenue from commercializing the platform, making it potential long-term upside rather than a near-term earnings driver. CVS’s Investor Day targets include mid-teens adjusted EPS growth through 2028. (investors.cvshealth.com)
This would preserve the turnaround thesis, although the immediate stock reaction could be muted after the recent run.
The consensus EPS number is a relatively low hurdle and sits close to the bottom of CVS’s first-half earnings cadence. The real hurdle is qualitative and segment-specific.
A constructive report must show that Aetna’s recovery is becoming less dependent on prior-year reserve development, that Caremark’s transition remains contained, and that the full-year outlook has at least as much upside as downside.
If CVS can deliver that combination, the company’s mid-teens growth framework through 2028 remains credible despite the stock’s strong rally. If underlying medical costs weaken or management becomes more cautious about the second half, investors are likely to question how much of the turnaround has already been reflected in the share price.
Market-price calculations use the provided Finnhub stock-price tool; financial figures are based primarily on CVS’s Q1 2026 release and call, Q2 2025 release, and 2025 Investor Day materials.